Speedy EU review for AbbVie’s pan-genotypic hep C therapy
European regulators are undertaking a speedy review of AbbVie’s investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530) (G/P) for the treatment of chronic hepatitis C (HCV) in all major genotypes.
Read More
